Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Institute for Physiology, Justus-Liebig University Giessen, Giessen, Germany.
Br J Pharmacol. 2020 Dec;177(23):5287-5311. doi: 10.1111/bph.14931. Epub 2020 Jan 17.
Hyperlipidaemia is a well-established risk factor for cardiovascular diseases and therefore, many animal model have been developed to mimic the human abnormal elevation of blood lipid levels. In parallel, extensive research for the alleviation of ischaemia/reperfusion injury has revealed that hyperlipidaemia is a major co-morbidity that attenuates the cardioprotective effect of conditioning strategies (preconditioning, postconditioning and remote conditioning) and that of pharmacological interventions by interfering with cardioprotective signalling pathways. In the present review article, we summarize the existing data on animal models of hypercholesterolaemia (total, low density and HDL abnormalities) and hypertriglyceridaemia used in ischaemia/reperfusion injury and protection from it. We also provide recommendations on preclinical animal models to be used for translations of the cardioprotective strategies into clinical practice. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc.
高脂血症是心血管疾病的一个明确的危险因素,因此,许多动物模型被开发出来以模拟人类血液脂质水平的异常升高。与此同时,为了缓解缺血/再灌注损伤而进行的广泛研究表明,高脂血症是一种主要的合并症,它通过干扰心脏保护信号通路,减弱了预处理、后处理和远程预处理等条件策略以及药物干预的心脏保护作用。在这篇综述文章中,我们总结了用于缺血/再灌注损伤及其保护的动物模型中存在的高胆固醇血症(总胆固醇、低密度脂蛋白和高密度脂蛋白异常)和高三酰甘油血症的数据。我们还就临床前动物模型提出了建议,以将心脏保护策略转化为临床实践。
本文是心脏保护中的危险因素、合并症和合并用药专题的一部分。要查看该部分的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc.